Mitapivat: Research, Dosing, and Where to Buy in 2026
A research-first profile for Mitapivat (Pyrukynd), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Mitapivat is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 1 transcript dosing protocol for Mitapivat, each linked to its source.
- Also indexed as Pyrukynd.
- 1 aggregated dosing-protocol mention from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Mitapivat?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Mitapivat Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| S1 | Does Cialis Decrease Your Workout Performance? Enhancing EPO for... | 00:14:25 | Avoid combining with DADA/DCA due to potential synergistic overlap on ATP synthesis and severe side effects | anecdotal |
Where to Buy Mitapivat in 2026
No tracked vendor recommendations for Mitapivat yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Mitapivat. Each line links to the original source.
- "Reduced annualized Vaso-occlusive episodes (VOE) rates compared to placebo by 51.6% (50 mg) and 70.0% (100 mg)." · Chaudhary S et al, 2025 PubMed
- "Statistically significant hemoglobin response was observed in 46.2%-56% of participants." · Chaudhary S et al, 2025 PubMed
- "However, SAEs were low, in 8%-19% of Mitapivat recipients." · Chaudhary S et al, 2025 PubMed
- "Between Nov 8, 2021, and March 31, 2023, 235 patients were screened, of whom 194 were enrolled (123 [63%] were female and 71 [37%] were male)." · Taher A et al, 2025 PubMed
- "55 (42%) of 130 patients in the mitapivat group had a haemoglobin response versus one (2%) of 64 in the placebo group (least-squares mean difference 41% [95% CI 32-50], two-sided p<0·0001)." · Taher A et al, 2025 PubMed
- "Adverse events were reported in 107 (83%) of 129 patients who received mitapivat and 50 (79%) of 63 patients who received placebo." · Taher A et al, 2025 PubMed
- "The most commonly reported adverse events with mitapivat were headache (29 [22%] of 129 patients in the mitapivat group vs six [10%] of 63 in the placebo group), initial insomnia (18 [14%] vs three [5%]), nausea (15 [12%] vs five [8%]), and upper respiratory tract infection (14 [11%] vs four [6%])." · Taher A et al, 2025 PubMed
- "Between Jan 19, 2022, and April 25, 2023, 79 patients were randomly assigned (51 [65%] female, 28 [35%] male; 46 [58%] Black or African American, 26 [33%] White, five [6%] multiracial, two [3%] Asian); 26 received mitapivat 50 mg, 26 received mitapivat 100 mg, and 27 received placebo, twice daily." · Idowu M et al, 2025 PubMed
- "Serious adverse events were reported in two (8%) of 26 patients in the mitapivat 50 mg group, four (15%) of 26 patients in the mitapivat 100 mg group, and three (11%) of 27 patients in the placebo group; grade 3 or worse adverse events occurred in three (12%), five (19%), and two (7%) patients, respectively." · Idowu M et al, 2025 PubMed
- "Mean changes from baseline in liver iron concentration by magnetic resonance imaging at week 96 in the M/M arm and the P/M arm were -2.0 mg Fe/g dry weight (dw; 95% CI, -4.8 to -0.8) and -1.8 mg Fe/g dw (95% CI, -4.4 to 0.80), respectively." · van Beers E et al, 2024 PubMed
Research and Studies
8 PubMed-indexed papers reference Mitapivat. Top 8 shown.
Legal Status
Mitapivat is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Mitapivat FDA-approved?
Mitapivat is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Mitapivat?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Mitapivat?
8 PubMed-indexed paper(s) reference Mitapivat in our current research feed. See the Research and Studies section above for citations.